Manel Juan
Overview
Explore the profile of Manel Juan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
139
Citations
3955
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Castellote-Borrell M, Domingo M, Merlina F, Lu H, Colell S, Bachiller M, et al.
ACS Appl Mater Interfaces
. 2025 Mar;
PMID: 40042178
Chimeric antigen receptor (CAR) T therapy has shown unprecedented results in clinical practice, including long-term complete responses. One of the current challenges of CAR T therapy is to optimize its...
2.
De Lucia A, Mazzotti L, Gaimari A, Zurlo M, Maltoni R, Cerchione C, et al.
Front Immunol
. 2025 Feb;
16:1515748.
PMID: 39995659
Over the past decades, significant progress has been made in the understanding of non-small cell lung cancer (NSCLC) biology and tumor progression mechanisms, resulting in the development of novel strategies...
3.
Guerrero-Murillo M, Rill-Hinarejos A, Trincado J, Bataller A, Ortiz-Maldonado V, Benitez-Ribas D, et al.
Cell Rep Med
. 2025 Feb;
:102026.
PMID: 39987917
No abstract available.
4.
Besliu C, Tanase A, Rotaru I, Espinoza J, Vidal L, Poelman M, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941892
Multiple myeloma is biologically and clinically a complex and heterogeneous disease which develops late in life, with the median age at the time of initial diagnosis being 66 years. In...
5.
Garcia-Corbacho J, Indacochea A, Victoria I, Moreno D, Angelats L, Gonzalez Navarro A, et al.
Cancer Immunol Immunother
. 2025 Feb;
74(3):85.
PMID: 39891724
Introduction: Immune check-point inhibitors (ICI) were a major breakthrough in cancer care, but optimal patient selection remains elusive in most tumors. Methods: Overall 173 adult patients with metastatic solid tumors...
6.
Mazzotti L, Borges de Souza P, Azzali I, Angeli D, Nanni O, Sambri V, et al.
HLA
. 2025 Jan;
105(1):e70011.
PMID: 39807702
COVID-19 remains a significant global health problem with uncertain long-term consequences for convalescents. We investigated the relationships between anti-N protein antibody levels, severe acute respiratory syndrome (SARS)-CoV-2-associated TCR repertoire parameters,...
7.
Jacobs J, Beekers I, Verkouter I, Richards L, Vegelien A, Bloemsma L, et al.
PLOS Digit Health
. 2025 Jan;
4(1):e0000464.
PMID: 39787064
Precision, or personalised medicine has advanced requirements for medical data management systems (MedDMSs). MedDMS for precision medicine should be able to process hundreds of parameters from multiple sites, be adaptable...
8.
Gomez-Puerta J, Monegal A, Ponce A, Peris P, Martinez-Cibrian N, Sarmiento-Monroy J, et al.
Semin Arthritis Rheum
. 2025 Jan;
71:152610.
PMID: 39754918
Introduction: Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a promising treatment for hematological malignancies. However, its association with immune-related complications such as rheumatic complications, is not well defined....
9.
Ballasch I, Lopez-Molina L, Galan-Ganga M, Sancho-Balsells A, Rodriguez-Navarro I, Borras-Pernas S, et al.
J Neuroinflammation
. 2024 Dec;
21(1):326.
PMID: 39695786
Schizophrenia is a complex multifactorial disorder and increasing evidence suggests the involvement of immune dysregulations in its pathogenesis. We observed that IKZF1 and IKZF2, classic immune-related transcription factors (TFs), were...
10.
Esquinas E, Moreno-Sanz A, Sanda V, Stodulski-Ciesla D, Borregon J, Pena-Blanque V, et al.
J Immunother Cancer
. 2024 Dec;
12(12.
PMID: 39694704
Background: Infusion of T cells modified with a chimeric antigen receptor (CAR) targeting CD19 has achieved exceptional responses in patients with non-Hodgkin's lymphoma (NHL), which led to the approval of...